Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy-Reference-Cited by-同舟云学术

Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy

Published:2012-07-11 Issue:2 Volume:119 Page:285-292
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Bauer Todd M.,El-Rayes Bassel F.,Li Xiaobai,Hammad Nazik,Philip Philip A.,Shields Anthony F.,Zalupski Mark M.,Bekaii-Saab Tanios

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.27734/fullpdf

Reference39 articles.

1. Cancer statistics, 2009;Jemal;CA Cancer J Clin.,2009

2. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma;Rothenberg;Cancer.,1996

3. Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography;Brambs;Endoscopy.,1993

4. Specific antigen in serum of patients with colon carcinoma;Koprowski;Science.,1981

5. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer;Boeck;Oncology.,2006

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel;Scientific Reports;2024-07-23

2. Extracellular volume-based scoring system for tracking tumor progression in pancreatic cancer patients receiving intraoperative radiotherapy;Insights into Imaging;2024-05-12

3. Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2;International Journal of Clinical Oncology;2024-03-17

4. Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial;World Journal of Gastrointestinal Oncology;2024-02-15

5. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel;2023-11-29